News & Events
Neurovance Announces Positive Centanafadine Phase 2b Results For Adult ADHD, And Plans For Phase 3 Trials
27 / 07 / 2016
Cell Innovation Partners, Japanese venture group, invests in Elastagen as part of a Second Close to the Series B Equity Financing.
21 / 06 / 2016
Ivantis Completes Enrollment in Pivotal HYDRUS IV Glaucoma Study of the HydrusTMMicrostent
21 / 06 / 2016
Viveve(R) Announces Pricing of $13.5 Million Public Offering of Shares of Common Stock and NASDAQ Uplisting
14 / 06 / 2016
Viveve(R) Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ
14 / 04 / 2016
Neurovance announces series of three clinical trials to support advanced development of Centanafadine (CTN) in adult ADHD
27 / 01 / 2016
Viveve(R) Announces Asia Pacific Distribution Partnership to Purchase a Minimum of 231 Systems
26 / 01 / 2016
Displaying records 26-44 of 44